甲状腺激素敏感性受损与糖尿病及代谢综合征相关
基于2007-2008年NHANES中5129名≥20岁美国代表性样本,研究计算了甲状腺激素抵抗指数(TFQI等)与糖尿病及代谢综合征的关联。结果显示TFQI最高四分位者糖化血红蛋白≥6.5%的OR为1.73,糖尿病用药OR为1.66,TFQI高于中位数者糖尿病相关死亡率的率比为4.81。结论认为甲状腺激素抵抗指数升高与肥胖、代谢综合征、糖尿病及糖尿病相关死亡相关。
要点
- TFQI最高四分位者糖化血红蛋白≥6.5%风险显著升高(OR 1.73)。
- TFQI高于中位数者糖尿病相关死亡率显著升高(率比4.81)。
- 甲状腺激素抵抗可能反映能量平衡问题,驱动2型糖尿病。
核心结论
- 甲状腺激素抵抗指数升高与肥胖、代谢综合征、糖尿病及糖尿病相关死亡相关。
- 甲状腺激素抵抗可能反映能量平衡问题,驱动2型糖尿病。
研究设计与样本
- 基于2007-2008年NHANES中5129名≥20岁美国代表性样本的横断面分析。
- 计算TFQI、Thyrotroph T4 Resistance Index和TSH Index,采用logistic和Poisson回归并调整性别、年龄和种族/族裔。
主要发现
- TFQI第四与第一四分位相比,糖化血红蛋白≥6.5%的OR为1.73(95%CI 1.32, 2.27),P趋势=0.002。
- TFQI第四与第一四分位相比,糖尿病用药的OR为1.66(95%CI 1.31, 2.10),P趋势=0.001。
- TFQI高于与低于中位数相比,糖尿病相关死亡的率比为4.81(95%CI 1.01, 22.94),P趋势=0.015。
- TFQI每增加1个标准差,糖尿病OR为1.13(95%CI 1.02, 1.25),代谢综合征OR为1.16(95%CI 1.02, 1.31)。
- 其他甲状腺激素抵抗指数对糖尿病相关死亡和代谢综合征显示类似关联。
临床怎么用
- 甲状腺激素抵抗指数可能有助于监测以能量平衡为重点的治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Diabetes prevalence and incidence increase among individuals with hypothyroidism but also among those with hyperthyroxinemia, which seems contradictory. Both high free thyroxine (fT4) and high thyroid-stimulating hormone (TSH) are present in the resistance to thyroid hormone syndrome. A mild acquired resistance to thyroid hormone might occur in the general population and be associated with diabetes. We aimed to analyze the association of resistance to thyroid hormone indices (the Thyroid Feedback Quantile-based Index [TFQI], proposed in this work, and the previously used Thyrotroph T4 Resistance Index and TSH Index) with diabetes. RESEARCH DESIGN AND METHODS: We calculated the aforementioned resistance to thyroid hormone indices based on a U.S. representative sample of 5,129 individuals ≥20 years of age participating in the 2007-2008 National Health and Nutrition Examination Survey (NHANES). Also, to approximate TFQI, a U.S.-referenced Parametric TFQI (PTFQI) can be calculated with the spreadsheet formula =NORM.DIST(fT4_cell_in_pmol_per_L,10.075,2.155,TRUE)+NORM.DIST(LN(TSH_cell_in_mIU_per_L),0.4654,0.7744,TRUE)-1. Outcomes of interest were glycohemoglobin ≥6.5%, diabetes medication, diabetes-related deaths (diabetes as contributing cause of death), and additionally, in a fasting subsample, diabetes and metabolic syndrome. Logistic and Poisson regressions were adjusted for sex, age, and race/ethnicity. RESULTS: Odd ratios for the fourth versus the first quartile of TFQI were 1.73 (95% CI 1.32, 2.27) (P trend = 0.002) for positive glycohemoglobin and 1.66 (95% CI 1.31, 2.10) (P trend = 0.001) for medication. Diabetes-related death rate ratio for TFQI being above versus below the median was 4.81 (95% CI 1.01, 22.94) (P trend = 0.015). Further adjustment for BMI and restriction to normothyroid individuals yielded similar results. Per 1 SD in TFQI, odds increased 1.13 (95% CI 1.02, 1.25) for diabetes and 1.16 (95% CI 1.02, 1.31) for metabolic syndrome. The other resistance to thyroid hormone indices showed similar associations for diabetes-related deaths and metabolic syndrome. CONCLUSIONS: Higher values in resistance to thyroid hormone indices are associated with obesity, metabolic syndrome, diabetes, and diabetes-related mortality. Resistance to thyroid hormone may reflect energy balance problems driving type 2 diabetes. These indices may facilitate monitoring treatments focused on energy balance.
引用
- Laclaustra M, Moreno-Franco B, Lou-Bonafonte JM, et al. Impaired Sensitivity to Thyroid Hormones Is Associated With Diabetes and Metabolic Syndrome. Diabetes Care. 2018. PMID: 30552134. doi:10.2337/dc18-1410
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。